Published in Antimicrob Agents Chemother on November 08, 2010
The requirement for nucleoporin NUP153 during human immunodeficiency virus type 1 infection is determined by the viral capsid. J Virol (2011) 2.44
HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor. Nucleic Acids Res (2012) 1.18
Differential sensitivities of retroviruses to integrase strand transfer inhibitors. J Virol (2011) 0.93
A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. Biomaterials (2013) 0.83
Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages. Antimicrob Agents Chemother (2011) 0.80
Enhanced autointegration in hyperstable simian immunodeficiency virus capsid mutants blocked after reverse transcription. J Virol (2013) 0.79
Identification of myxobacteria-derived HIV inhibitors by a high-throughput two-step infectivity assay. Microb Cell Fact (2013) 0.78
Polymorphic LEDGF/p75 variants support efficient HIV-1 infection ex vivo. AIDS (2013) 0.77
Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells. PLoS One (2017) 0.75
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 22.26
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature (1990) 5.70
Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science (1990) 5.49
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr (2006) 4.71
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem (2008) 3.09
HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci U S A (2000) 3.00
Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol (2002) 2.89
Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol (2001) 2.79
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther (2007) 2.53
Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother (1993) 2.52
L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1995) 2.39
Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol (2005) 2.23
The post-antibiotic effect. J Antimicrob Chemother (1993) 2.15
Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science (2004) 2.12
Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem (2006) 2.03
Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci U S A (1992) 1.89
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet (2001) 1.87
Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J Antimicrob Chemother (1993) 1.77
Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res (2009) 1.64
Human immunodeficiency virus type 1 replication in the absence of integrase-mediated dna recombination: definition of permissive and nonpermissive T-cell lines. J Virol (2001) 1.63
Structural basis for functional tetramerization of lentiviral integrase. PLoS Pathog (2009) 1.53
Human macrophages support persistent transcription from unintegrated HIV-1 DNA. Virology (2007) 1.46
Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine. Antimicrob Agents Chemother (2007) 1.43
A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2002) 1.43
Genetic analyses of conserved residues in the carboxyl-terminal domain of human immunodeficiency virus type 1 integrase. J Virol (2005) 1.28
Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr (2004) 1.26
Synchronized infection of cell cultures by magnetically controlled virus. J Virol (2005) 1.14
New class of HIV integrase inhibitors that block viral replication in cell culture. Curr Biol (2002) 1.13
HIV pathogenesis: 25 years of progress and persistent challenges. AIDS (2009) 1.11
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Antimicrob Agents Chemother (2008) 1.10
Synchronous infection of SIV and HIV in vitro for virology, immunology and vaccine-related studies. Nat Protoc (2010) 1.08
Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain. J Virol (2009) 1.06
Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology (2009) 1.05
Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. Curr Opin Investig Drugs (2009) 0.95
Antiretroviral therapy in the clinic. J Virol (2010) 0.95
Human immunodeficiency virus type 1 tropism for human macrophages. Pathobiology (1992) 0.86
Intracellular metabolism of CycloSaligenyl 3'-azido-2', 3'-dideoxythymidine monophosphate, a prodrug of 3'-azido-2', 3'-dideoxythymidine (zidovudine). Mol Pharmacol (1999) 0.85
Pharmacodynamics of antiretroviral chemotherapy. Infect Control Hosp Epidemiol (1993) 0.85
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors. Antimicrob Agents Chemother (2008) 0.84
Assessment of the susceptibility of mutant HIV-1 to antiviral agents. J Virol Methods (2010) 0.84
Sensitive enzyme immunoassay for measuring plasma and intracellular nevirapine levels in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2004) 0.82
Identification of host proteins required for HIV infection through a functional genomic screen. Science (2008) 12.44
Retroviral intasome assembly and inhibition of DNA strand transfer. Nature (2010) 4.99
LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev (2007) 3.96
Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Natl Acad Sci U S A (2005) 3.18
Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe (2010) 3.08
Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol (2007) 2.95
Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase. J Biol Chem (2004) 2.64
The requirement for nucleoporin NUP153 during human immunodeficiency virus type 1 infection is determined by the viral capsid. J Virol (2011) 2.44
Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat Struct Mol Biol (2012) 2.36
Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. J Virol (2006) 2.32
Human cell proteins and human immunodeficiency virus DNA integration. Front Biosci (2004) 2.32
Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75. Nat Struct Mol Biol (2005) 2.17
Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc Natl Acad Sci U S A (2010) 2.16
A tripartite DNA-binding element, comprised of the nuclear localization signal and two AT-hook motifs, mediates the association of LEDGF/p75 with chromatin in vivo. Nucleic Acids Res (2006) 2.02
The requirement for cellular transportin 3 (TNPO3 or TRN-SR2) during infection maps to human immunodeficiency virus type 1 capsid and not integrase. J Virol (2009) 1.99
A novel co-crystal structure affords the design of gain-of-function lentiviral integrase mutants in the presence of modified PSIP1/LEDGF/p75. PLoS Pathog (2009) 1.89
Requirements for capsid-binding and an effector function in TRIMCyp-mediated restriction of HIV-1. Virology (2006) 1.80
The barrier-to-autointegration factor is a component of functional human immunodeficiency virus type 1 preintegration complexes. J Virol (2003) 1.76
Lens epithelium-derived growth factor fusion proteins redirect HIV-1 DNA integration. Proc Natl Acad Sci U S A (2010) 1.68
Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin. J Cell Sci (2006) 1.67
Wild-type levels of nuclear localization and human immunodeficiency virus type 1 replication in the absence of the central DNA flap. J Virol (2002) 1.62
Dynamic modulation of HIV-1 integrase structure and function by cellular lens epithelium-derived growth factor (LEDGF) protein. J Biol Chem (2008) 1.61
Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem (2012) 1.55
Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol (2011) 1.55
Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection. Proc Natl Acad Sci U S A (2006) 1.53
Structural basis for functional tetramerization of lentiviral integrase. PLoS Pathog (2009) 1.53
The host proteins transportin SR2/TNPO3 and cyclophilin A exert opposing effects on HIV-1 uncoating. J Virol (2012) 1.52
Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation. Proc Natl Acad Sci U S A (2013) 1.49
Identification and characterization of a functional nuclear localization signal in the HIV-1 integrase interactor LEDGF/p75. J Biol Chem (2004) 1.47
Structural biology of retroviral DNA integration. Virology (2011) 1.37
Nucleoporin NUP153 phenylalanine-glycine motifs engage a common binding pocket within the HIV-1 capsid protein to mediate lentiviral infectivity. PLoS Pathog (2013) 1.36
Human immunodeficiency virus type 1 capsid mutation N74D alters cyclophilin A dependence and impairs macrophage infection. J Virol (2012) 1.35
Wild-type levels of human immunodeficiency virus type 1 infectivity in the absence of cellular emerin protein. J Virol (2006) 1.33
Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase. J Virol (2005) 1.30
The SET complex acts as a barrier to autointegration of HIV-1. PLoS Pathog (2009) 1.28
Genetic analyses of conserved residues in the carboxyl-terminal domain of human immunodeficiency virus type 1 integrase. J Virol (2005) 1.28
Identification and characterization of PWWP domain residues critical for LEDGF/p75 chromatin binding and human immunodeficiency virus type 1 infectivity. J Virol (2008) 1.27
Subunit-specific protein footprinting reveals significant structural rearrangements and a role for N-terminal Lys-14 of HIV-1 Integrase during viral DNA binding. J Biol Chem (2007) 1.26
Differential effects of human immunodeficiency virus type 1 capsid and cellular factors nucleoporin 153 and LEDGF/p75 on the efficiency and specificity of viral DNA integration. J Virol (2012) 1.24
Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain. J Virol (2009) 1.23
Retroviral integrase proteins and HIV-1 DNA integration. J Biol Chem (2012) 1.20
HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor. Nucleic Acids Res (2012) 1.18
Structure-based mutagenesis of the integrase-LEDGF/p75 interface uncouples a strict correlation between in vitro protein binding and HIV-1 fitness. Virology (2006) 1.17
The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem (2013) 1.14
Intracellular transport of human immunodeficiency virus type 1 integrase. J Cell Sci (2003) 1.10
Molecular mechanisms of HIV integration and therapeutic intervention. Expert Rev Mol Med (2007) 1.08
LEDGF/p75 interferes with the formation of synaptic nucleoprotein complexes that catalyze full-site HIV-1 DNA integration in vitro: implications for the mechanism of viral cDNA integration. Virology (2007) 1.08
Chromatinized templates reveal the requirement for the LEDGF/p75 PWWP domain during HIV-1 integration in vitro. Nucleic Acids Res (2008) 1.07
Transcriptional co-activator LEDGF interacts with Cdc7-activator of S-phase kinase (ASK) and stimulates its enzymatic activity. J Biol Chem (2009) 1.04
Viral and cellular requirements for the nuclear entry of retroviral preintegration nucleoprotein complexes. Viruses (2013) 1.03
Lys-34, dispensable for integrase catalysis, is required for preintegration complex function and human immunodeficiency virus type 1 replication. J Virol (2005) 1.01
HIV DNA is heavily uracilated, which protects it from autointegration. Proc Natl Acad Sci U S A (2011) 1.00
Biochemical and virological analysis of the 18-residue C-terminal tail of HIV-1 integrase. Retrovirology (2009) 0.99
Structural basis for nuclear import of splicing factors by human Transportin 3. Proc Natl Acad Sci U S A (2014) 0.98
HIV-1 incorporates and proteolytically processes human NDR1 and NDR2 serine-threonine kinases. Virology (2005) 0.96
Integrase residues that determine nucleotide preferences at sites of HIV-1 integration: implications for the mechanism of target DNA binding. Nucleic Acids Res (2014) 0.96
Impairment of human immunodeficiency virus type-1 integrase SUMOylation correlates with an early replication defect. J Biol Chem (2011) 0.95
Simian virus 40-based replication of catalytically inactive human immunodeficiency virus type 1 integrase mutants in nonpermissive T cells and monocyte-derived macrophages. J Virol (2004) 0.94
In vivo biotinylation and capture of HIV-1 matrix and integrase proteins. J Virol Methods (2009) 0.94
Differential sensitivities of retroviruses to integrase strand transfer inhibitors. J Virol (2011) 0.93
Multimodal mechanism of action of allosteric HIV-1 integrase inhibitors. Expert Rev Mol Med (2013) 0.92
Herpes simplex virus type 1 preferentially targets human colon carcinoma: role of extracellular matrix. J Virol (2007) 0.91
The selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques. J Virol (2013) 0.86
Biochemical characterization of novel retroviral integrase proteins. PLoS One (2013) 0.81
Transgenic mouse with the herpes simplex virus type 1 latency-associated gene: expression and function of the transgene. J Virol (2003) 0.80
Thermal stability of the human immunodeficiency virus type 1 (HIV-1) receptors, CD4 and CXCR4, reconstituted in proteoliposomes. PLoS One (2010) 0.78
Polymorphic LEDGF/p75 variants support efficient HIV-1 infection ex vivo. AIDS (2013) 0.77
Retroviral Integrase Structure and DNA Recombination Mechanism. Microbiol Spectr (2014) 0.77
Viral latency and potential eradication of HIV-1. Expert Rev Anti Infect Ther (2012) 0.77
Mechanistic and pharmacological analyses of HIV-1 integration. Methods (2009) 0.75
General guidelines for experimenting with HIV. Curr Protoc Immunol (2004) 0.75